Quadrant Capital Group LLC Cellectis S.A. Transaction History

Quadrant Capital Group LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$2.39 - $4.93 $2,476 - $5,107	-1,036 Closed	0 $0
Q1 2022 May 06, 2022	SELL	$3.45 - $8.77 $2,870 - $7,296	-832 Reduced 44.54%	1,036 $5,000
Q4 2021 Feb 01, 2022	BUY	$8.01 - $12.84 $7,417 - $11,889	926 Added 98.3%	1,868 $15,000
Q3 2021 Nov 12, 2021	BUY	$11.94 - $16.09 $2,961 - $3,990	248 Added 35.73%	942 $12,000
Q2 2021 Aug 09, 2021	BUY	$14.36 - $20.93 $9,965 - $14,525	694 New	694 $11,000
Q1 2020 May 15, 2020	SELL	$7.81 - $18.82 $2,819 - $6,794	-361 Closed	0 $0
Q4 2019 Feb 03, 2020	BUY	$9.73 - $19.31 $3,512 - $6,970	361 New	361 $6,000

11.2M

2.8K

17.9K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $82.8M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

Stay updated on Quadrant Capital Group LLC with notifications on news.